Chick-fil-A Inc., an American restaurant chain specializing in chicken sandwiches, announced it will no longer serve chicken that is antibiotic-free. This decision reversed the brand's long-time pledge of "No Antibiotics Ever."
Why Chick-fil-A Changed Its Stance
According to Associated Press News, Chick-fil-A's move was prompted by the predicted supply shortage. This is also a sudden change of heart from its vow not to use chicken fed with antibiotics.
For years, Chick-fil-A has committed to serving only antibiotic-free chickens. The chain explained that this pledge is intended to help prevent human antibiotic resistance related to the widespread use of the drugs in most livestock production.
A Shift to Standard NAIHM
The restaurant announced it would now embrace a standard called the "no antibiotics important to human medicine" (NAIHM), which means it would allow some antibiotics. The NAIHM involves steering clear of certain medications that are commonly used for the treatment of humans and restricting the usage of animal antibiotics to particular instances of animal illness.
Chick-fil-A shared that it will apply the new NAIHM policy starting this spring. Through its spokesperson, the company said this move mirrors its concerns about its capability to obtain enough supplies of antibiotic-free chicken.
"To maintain supply of the high-quality chicken you expect from us, Chick-fil-A will shift from No Antibiotics Ever (NAE) to No Antibiotics Important To Human Medicine (NAIHM) starting in the Spring of 2024," Chick-fil-A said in a statement.
The fast-food chain added, "NAE means no antibiotics of any kind were used in raising the animal. NAIHM restricts the use of those antibiotics that are important to human medicine and commonly used to treat people, and allows the use of animal antibiotics only if the animal and those around it were to become sick."
Photo by: Malhar Patel/Unsplash


Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Washington Post Publisher Will Lewis Steps Down After Layoffs
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 



